Hypolipidemic Agents/therapeutic use* ; Lipids

Anticholesteremic Agents/therapeutic use* ; Cholesterol, LDL ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypolipidemic Agents/therapeutic use* ; Lipids

Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; therapeutic use ; Hypolipidemic Agents ; therapeutic use ; Pharmacogenetics

To evaluate the clinical efficacy and safety of berberine in the treatment of dyslipidemia. In this review, CNKI, WanFang, VIP, CBM, PubMed, Cochrane Library, EMbase, and Medline(OVID) were retrieved from database establishment to January, 2019 in any language. Randomized controlled trials(RCTs) of berberine with or without lipid-lowering drugs vs placebo, without drugs or lipid-lowering drugs only in treatment of dyslipidemia were collected. Data extraction and paper quality assessment were conducted according to the Cochrane Handbook. Then RevMan 5.3 software was used for Meta-analysis. A total of 25 trials were included, covering 3 042 cases, including 1 552 cases in the experimental group and 1 490 cases in the control group. The clinical heterogeneity of the included trials was relatively high, and the methodological quality of most trials was generally low, with bias in terms of random sequence generation, allocation hiding, blind method and result data. Interventions were divided into different subgroups for analysis. Meta-analysis suggested that use berberine alone or along with lipid lowing drugs could reduce TC, TG, LDL-C levels and increased HDL-C levels with statistically significant difference as compared with control group. As compared with control group, there was no statistically significant difference in the incidence of adverse events. No severe adverse effects were reported in all trials. Berberine has good efficacy and safety in the treatment of dyslipidemia. Due to the quality limitations of the included trials, the above conclusions need to be further verified by high-quality, large sample size and multi-center clinical trials.
Berberine/therapeutic use* ; Dyslipidemias/drug therapy* ; Humans ; Hypolipidemic Agents/therapeutic use* ; Lipids ; Randomized Controlled Trials as Topic

Antioxidants ; therapeutic use ; Fatty Liver ; drug therapy ; Humans ; Hypoglycemic Agents ; therapeutic use ; Hypolipidemic Agents ; therapeutic use ; Metformin ; therapeutic use ; Quaternary Ammonium Compounds ; therapeutic use ; Vitamin E ; therapeutic use

Cardiovascular Diseases ; drug therapy ; prevention & control ; Humans ; Hypolipidemic Agents ; administration & dosage ; therapeutic use ; Risk Reduction Behavior

Coronary Disease ; drug therapy ; Humans ; Hypolipidemic Agents ; administration & dosage ; therapeutic use

Dyslipidemias/drug therapy* ; Humans ; Hypolipidemic Agents/therapeutic use* ; Lipids ; Pharmaceutical Preparations

Adult ; Biphenyl Compounds ; therapeutic use ; Fatty Liver ; drug therapy ; Female ; Humans ; Hypolipidemic Agents ; therapeutic use ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; Phosphatidylcholines ; therapeutic use ; Young Adult

OBJECTIVETo compare the lipid lowering effects of Zhikang Granule (ZKG) and simvastatin.

METHODSForty-five out-patients with hyperlipemia who met the entry criteria were enrolled and randomized into two groups in the ratio of 2: 1, 30 patients in the ZKG group and 15 patients in the simvastatin group. The lipid lowering effects and safety of treatment during the 24-week therapeutic period, as well as the influence of treatment on plasma high sensitivity C reactive protein (hs-CRP) level in patients were observed.

RESULTSNo significant difference between the two groups was observed in serum levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C) and triglyceride (TG) at the 4th, 8th, 12th and 24th week (P > 0.05). However, as compared with baseline, significant reduction of TC and LDL-C in both groups was shown at all the observing time points (P < 0.01), while the changes in TG and HDL-C were insignificant (P > 0.05). The control rates of LDL-C and TC in the ZKG group and the simvastatin group were 86.7% (26/30) versus 100% (15/15) at the 4th week, 80.0% (24/30) versus 100% (15/15) at the 8th week, 53.3% (16/30) versus 60.0% (9/15) at the 12th week, and 90.0% (27/30) versus 93.3% (14/15) at the 24th week, respectively, all showed insignificant difference between groups. No statistical differences were found between groups in levels of plasma transaminase, creatinine, uric acid and hs-CRP (P > 0.05).

CONCLUSIONZKG has a definite effect in lowering LDL-C and TC, and it is safe in long-term administration.

Aged ; C-Reactive Protein ; analysis ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Hyperlipidemias ; drug therapy ; Hypolipidemic Agents ; therapeutic use ; Lipids ; blood ; Male ; Middle Aged ; Phytotherapy ; Simvastatin ; therapeutic use